1 |
Health Insurance Review and Assessment Service (HIRA). Improvement of patients' access of drugs for 4 major diseases. 2016.
|
2 |
Ministry of Health and Welfare (MOHW). Health insurance coverage for high-priced drugs such as targeted cancer drugs is expanded. Available from http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&BOARD_ID=140&BOARD_FLAG=00&CONT_SEQ=290962&page=1. Accessed July 28, 2017.
|
3 |
Lee YS, Bae SJ, Lee BR, et al. Review of Risk Sharing Arrangements in Some Developed Countries: Focusing on Type of Contracts and Management System. J Health Tech Assess 2017;5(1):13-21.
|
4 |
Health Insurance Review and Assessment Service (HIRA). Detailed evaluation criteria for drugs subject to negotiation include new drugs, etc. Available from http://www.hira.or.kr. Accessed July 28, 2017.
|
5 |
Health Insurance Review and Assessment Service (HIRA). Regulation for evaluation criteria and procedures for reimbursement eligibility of drugs. 2016.
|
6 |
Klemp M, Fronsdal KB, Facey K, et al. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 2011;27(1):77-83.
DOI
|
7 |
Spoors J. Patient access schemes in the new NHS. Brit J Healthc Manag 2012;18(8):412-8.
DOI
|
8 |
Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health Policy 2014;117(3):345-52.
DOI
|
9 |
Garattini L, Casadei G. Risk sharing agreements: What lessons from Italy? Int J Technol Assess 2011;27(2):169-72.
DOI
|
10 |
Cheong C, Son KB, Bae EY. Risk Sharing Agreements on Pharmaceuticals: Lessons from Foreign Countries' Experience. J Health Tech Assess 2013;1(1):51-60.
|
11 |
Managed entry agreements for pharmaceuticals: the European experience. Available from http://eprints.lse.ac.uk/50513/. Accessed July 28, 2017.
|
12 |
List of technologies with approved Patient Access Schemes. Available from https://www.nice.org.uk/About/What-we-do/Patient-access-schemes-liaison-unit/. Accessed July 28, 2017.
|
13 |
Health Insurance Review and Assessment Service (HIRA), Seoul National University. A study on the post-listed management of the drug that listed by risk sharing management. 2016.
|